{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:59:06Z","timestamp":1790470746799,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.heliyon.2023.e16542","type":"journal-article","created":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T19:26:00Z","timestamp":1684610760000},"page":"e16542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock"],"prefix":"10.1016","volume":"9","author":[{"given":"Yang","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.heliyon.2023.e16542_bib1","first-page":"573","article-title":"Sepsis and Septic Shock - basics of diagnosis, pathophysiology and clinical decision making","volume":"104","author":"Font","year":"2020","journal-title":"Med. Clin."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16542_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1164\/rccm.201504-0781OC","article-title":"Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations","volume":"193","author":"Fleischmann","year":"2016","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e16542_bib3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s13054-018-2186-7","article-title":"Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: the FORECAST study","volume":"22","author":"Abe","year":"2018","journal-title":"Crit. Care"},{"issue":"10141","key":"10.1016\/j.heliyon.2023.e16542_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","article-title":"Sepsis and septic shock","volume":"392","author":"Cecconi","year":"2018","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.heliyon.2023.e16542_bib5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e16542_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/CCM.0000000000002210","article-title":"Right dose, right now: customized drug dosing in the critically ill","volume":"45","author":"Roberts","year":"2017","journal-title":"Crit. Care Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16542_bib7","doi-asserted-by":"crossref","first-page":"690.e1","DOI":"10.1016\/j.ajem.2019.09.011","article-title":"Meropenem as an antidote for intentional valproic acid overdose","volume":"38","author":"Thomas","year":"2020","journal-title":"Am. J. Emerg. Med."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e16542_bib8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1177\/0885066618784264","article-title":"Evaluation of meropenem extended versus intermittent infusion dosing protocol in critically ill patients","volume":"35","author":"Ahmed","year":"2020","journal-title":"J. Intensive Care Med."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16542_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14787210.5.3.365","article-title":"Piperacillin-tazobactam: a beta-lactam\/beta-lactamase inhibitor combination","volume":"5","author":"Gin","year":"2007","journal-title":"Expert Rev. Anti Infect. Ther."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16542_bib10","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.01917-17","article-title":"Point-counterpoint: piperacillin-tazobactam should Be used to treat infections with extended-spectrum-beta-lactamase-positive organisms","volume":"56","author":"Schuetz","year":"2018","journal-title":"J. Clin. Microbiol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e16542_bib11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e16542_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e16542_bib13","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1097\/CCM.0b013e318250aa72","article-title":"The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*","volume":"40","author":"Labelle","year":"2012","journal-title":"Crit. Care Med."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e16542_bib14","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/CCM.0000000000000516","article-title":"Using the number needed to treat to assess appropriate antimicrobial therapy as a determinant of outcome in severe sepsis and septic shock","volume":"42","author":"Vazquez-Guillamet","year":"2014","journal-title":"Crit. Care Med."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e16542_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s00101-010-1719-5","article-title":"[Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k guidelines of the German sepsis society (DSG) and the German interdisciplinary association for intensive and emergency care medicine (DIVI)]","volume":"59","author":"Reinhart","year":"2010","journal-title":"Anaesthesist"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e16542_bib16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1007\/s001340050931","article-title":"The use of maximum SOFA score to quantify organ dysfunction\/failure in intensive care. Results of a prospective, multicentre study. Working Group on Sepsis related Problems of the ESICM","volume":"25","author":"Moreno","year":"1999","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.heliyon.2023.e16542_bib17","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s13063-014-0541-9","article-title":"Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial","volume":"16","author":"Harris","year":"2015","journal-title":"Trials"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e16542_bib18","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e16542_bib19","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16542_bib20","doi-asserted-by":"crossref","first-page":"430","DOI":"10.3747\/pdi.2017.00274","article-title":"Stability of meropenem and piperacillin\/tazobactam with heparin in various peritoneal dialysis solutions","volume":"38","author":"Mendes","year":"2018","journal-title":"Perit. Dial. Int."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e16542_bib21","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s12185-020-03031-4","article-title":"Meropenem versus piperacillin\/tazobactam for febrile neutropenia in pediatric patients: efficacy of piperacillin\/tazobactam as a 1-h drip infusion four times a day","volume":"113","author":"Kobayashi","year":"2021","journal-title":"Int. J. Hematol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e16542_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00276-17","article-title":"Piperacillin-tazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC \u03b2-lactamase-producing enterobacteriaceae","volume":"61","author":"Cheng","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.heliyon.2023.e16542_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2334-10-72","article-title":"Comparative in vitro activity of Meropenem, Imipenem and Piperacillin\/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study","volume":"10","author":"Joly-Guillou","year":"2010","journal-title":"BMC Infect. Dis."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023037490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023037490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T00:23:36Z","timestamp":1790468616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023037490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2405844023037490"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16542","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e16542"}}